Callio Therapeutics, a biotechnology company focused on realizing the promise of multi-payload antibody-drug conjugates (ADCs ...

HER2 (also known as ERBB2) is a key oncogene in breast cancer and is found in 2–4% of patients with non-small-cell lung ...

In a Chinese trial, trastuzumab rezetecan induced a 73% response rate in previously treated HER2-mutant non-small cell lung ...

AstraZeneca and Daiichi Sankyo's Enhertu has become the first HER2-directed drug to mount a patient survival benefit in a ...

Frazier Life Sciences has launched Callio Therapeutics with $187 million in series A funds and a HER2-targeted dual-payload ...

Oqory’s planned reverse merger with fellow antibody-drug conjugate (ADC) company Vincerx Pharma has fallen apart at the last ...

Frazier Life Sciences launched Callio Therapeutics, a cancer startup headquartered in Seattle and Singapore. Frazier led ...

We were very pleased that the private placement was supported by existing investors and our Board of Directors, all of whom participated in this financing,” said Samir R. Patel, MD, President and CEO ...

Callio Therapeutics, which has dual headquarters in Seattle and Singapore, launched Monday with a $187 million Series A round ...

The presentation will be accessible through the News & Events page of the Investor Relations section of the company’s website at www.sutrobio.com. An archived replay will be available for at least 30 ...

Researchers at The University of Texas MD Anderson Cancer Center have developed a novel antibody-toxin conjugate (ATC) designed to stimulate immune-mediated eradication of tumors.